Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide.
What is Charles River Laboratories International's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CRL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CRL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of Charles River Laboratories International's salary, the management and board of directors tenure and is there insider trading?
4.5yrs
Average management tenure
CEO
JamesFoster(68yo)
27.9yrs
Tenure
US$14,450,802
Compensation
Mr. James C. Foster, J.D., has been the Chairman of the Board of Charles River Laboratories, Inc. (“CRL”) since 2000 and has been its Chief Executive Officer since 1992. Mr. Foster has been the President o ...
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD14.45M) is above average for companies of similar size in the US market ($USD6.81M).
Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.
Management Age and Tenure
4.5yrs
Average Tenure
55yo
Average Age
Experienced Management: CRL's management team is considered experienced (4.5 years average tenure).
Board Age and Tenure
11.2yrs
Average Tenure
68yo
Average Age
Experienced Board: CRL's board of directors are seasoned and experienced ( 11.2 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
SellUS$502,12230 May 19
William Barbo
Entity
Individual
Role
Senior Key Executive
Chief Commercial Officer & Executive VP
Shares
4,000
Max Price
US$126.19
SellUS$189,39212 Mar 19
Joseph LaPlume
Entity
Individual
Shares
1,370
Max Price
US$138.37
SellUS$635,20101 Mar 19
William Barbo
Entity
Individual
Role
Senior Key Executive
Chief Commercial Officer & Executive VP
Shares
4,500
Max Price
US$141.38
SellUS$25,88612 Dec 18
James Foster
Entity
Individual
Role
Chief Executive Officer
Chairman
Shares
200
Max Price
US$129.43
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
David Johst (57yo)
Executive VP of Human Resources
Tenure: 23.9yrs
Compensation: US$5.27m
James Foster (68yo)
Chairman
Tenure: 27.9yrs
Compensation: US$14.45m
Amy Cianciaruso
Corporate Vice President of Public Relations & Corporate Communications
Tenure: 0yrs
William Barbo (58yo)
Chief Commercial Officer & Executive VP
Tenure: 3.2yrs
Compensation: US$2.58m
Michael Knell (42yo)
Corporate Senior VP & Chief Accounting Officer
Tenure: 2.7yrs
David Smith (53yo)
Corporate Executive VP & CFO
Tenure: 4.3yrs
Compensation: US$3.24m
Birgit Girshick (49yo)
EVP of Discovery & Safety Assessment
Tenure: 6.2yrs
Compensation: US$2.52m
Shanna Cotti-Osmanski
Chief Information Officer & Corporate Senior VP of Information Technology
Tenure: 4.6yrs
Barbara Patterson
Senior Vice President of Regulatory Affairs & Compliance
Tenure: 3.9yrs
Todd Spencer
Corporate Vice President of Investor Relations
Tenure: 0yrs
Board Members
Stephen Chubb (75yo)
Independent Director
Tenure: 25.9yrs
Compensation: US$280.05k
C. Reese (74yo)
Independent Director
Tenure: 12yrs
Compensation: US$290.05k
Richard Wallman (68yo)
Independent Director
Tenure: 8.9yrs
Compensation: US$285.05k
James Foster (68yo)
Chairman
Tenure: 27.9yrs
Compensation: US$14.45m
George Milne (75yo)
Lead Director
Tenure: 0yrs
Compensation: US$305.05k
Jean-Paul Mangeolle (57yo)
Independent Director
Tenure: 1.9yrs
Compensation: US$280.05k
George Massaro (71yo)
Independent Director
Tenure: 16.9yrs
Compensation: US$300.05k
Bob Bertolini (58yo)
Independent Director
Tenure: 8.9yrs
Compensation: US$295.05k
Martin MacKay (63yo)
Independent Director
Tenure: 2.4yrs
Compensation: US$275.05k
Deborah Kochevar (62yo)
Independent Director
Tenure: 11.2yrs
Compensation: US$275.05k
Company Information
Charles River Laboratories International, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
Name: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segm ...
Company Analysis and Financial Data Status
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2019/12/07 23:33
End of Day Share Price
2019/12/06 00:00
Earnings
2019/09/28
Annual Earnings
2018/12/29
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.